- Do the efficacy data support approval of avacopan for the treatment of adult patients with AAV (granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA))? If you voted “No”, what data are needed? Y-9, N-9
- Is the safety profile of avacopan adequate to support approval of avacopan for the treatment of adult patients with AAV (GPA and MPA)? If you voted “No”, what data are needed? Y-10, N-8
- Is the benefit-risk profile adequate to support approval of avacopan at the proposed dose of 30 mg twice daily for the treatment of adult patients with AAV (GPA and MPA)? If you voted “No”, what further data are needed? Y-10, N-8

ChemoCentryx’s Avacopan May Need Another Trial After Tepid Advisory Committee Vote

More from US FDA Performance Tracker